Recombinant latent transforming growth factor beta 1 has a longer plasma half-life in rats than active transforming growth factor beta 1, and a different tissue distribution.
Open Access
- 1 December 1990
- journal article
- research article
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 86 (6) , 1976-1984
- https://doi.org/10.1172/jci114932
Abstract
Transforming growth factor beta 1 (TGF-beta 1) is a key regulator of cell growth and differentiation. Under normal physiological conditions, it is made as a biologically latent complex whose significance is unknown. Previous work has indicated that active TGF-beta 1 has a very short plasma half-life in rats (Coffey, R. J., L. J. Kost, R. M. Lyons, H. L. Moses, and N. F. La-Russo. 1987. J. Clin. Invest. 80:750-757). We have investigated the possibility that latent complex formation may extend the plasma half-life of TGF-beta 1 and alter its organ distribution. Radiolabeled latent TGF-beta 1 was formed by noncovalent association of 125I-TGF-beta 1 with the TGF-beta 1 precursor "pro" region from recombinant sources. TGF-beta 1 in this latent complex had a greatly extended plasma half-life (greater than 100 min) in rats compared with active TGF-beta 1 (2-3 min). Whereas active TGF-beta 1 was rapidly taken up by the liver, kidneys, lungs, and spleen and degraded, TGF-beta 1 in the latent complex was largely confined to the circulation, and was less than 5% degraded after 90 min. The pharmacokinetics of TGF-beta 1 in the latent complex were shown to be critically dependent on the degree of sialylation of the complex. The results suggest that formation of latent complexes may switch endogenous TGF-beta 1 from an autocrine/paracrine mode of action to a more endocrine mode involving target organs distant from the site of synthesis.This publication has 27 references indexed in Scilit:
- Inhibition and Promotion of Differentiated-Like Phenotype of a Human Lung Carcinoma in Athymic Mice by Natural and Recombinant Forms of Transforming Growth Factor-betaJNCI Journal of the National Cancer Institute, 1989
- Inhibition of early murine hemopoietic progenitor cell proliferation after in vivo locoregional administration of transforming growth factor-beta 1.The Journal of Immunology, 1989
- Transforming growth factor-beta activity is potentiated by heparin via dissociation of the transforming growth factor-beta/alpha 2-macroglobulin inactive complex.The Journal of cell biology, 1989
- Inhibition of endothelial cell movement by pericytes and smooth muscle cells: activation of a latent transforming growth factor-beta 1-like molecule by plasmin during co-culture.The Journal of cell biology, 1989
- Transforming Growth Factor β: Biochemistry and Roles in Embryogenesis, Tissue Repair and Remodeling, and CarcinogenesisPublished by Elsevier ,1988
- Characterization of a membrane receptor for transforming growth factor-beta in normal rat kidney fibroblasts.Journal of Biological Chemistry, 1984
- Distribution of ?2-macroglobulin in normal, inflammatory, and tumor tissues in ratsInflammation, 1984
- Isolation and expression of an altered mouse dihydrofolate reductase cDNA.Proceedings of the National Academy of Sciences, 1983
- Carbohydrate-Specific Receptors of the LiverAnnual Review of Biochemistry, 1982
- Isolation of Chinese hamster cell mutants deficient in dihydrofolate reductase activity.Proceedings of the National Academy of Sciences, 1980